Sherry Kropatsch, APRN
Psychiatric/Mental Health · Grand Island, NENPI 1851762785
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,042 of the $11,389 with a category attached, or 79.4%. It is spread thinly across 22 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 569 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Brainsway USA Inc$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$690
- Supernus Pharmaceuticals, Inc.$568
- Alkermes, Inc.$557
- plus $4K from 16 others
What the payments were for
- Speaking & faculty fees$2,29920%
- Food & beverage$9,04279%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 199 | $2,427 |
| Brainsway USA Inc | 2 | $2,320 |
| Otsuka America Pharmaceutical, Inc. | 105 | $1,302 |
| Lundbeck LLC | 43 | $690 |
| Supernus Pharmaceuticals, Inc. | 26 | $568 |
| Alkermes, Inc. | 24 | $557 |
| Axsome Therapeutics, Inc. | 19 | $532 |
| Johnson & Johnson | 23 | $468 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $395 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $384 |
| E.r. Squibb & Sons, L.L.C. | 16 | $292 |
| Neurocrine Biosciences, Inc. | 11 | $291 |
| Ironshore Pharmaceuticals Inc. | 18 | $290 |
| Vanda Pharmaceuticals Inc. | 11 | $189 |
| Corium, LLC | 7 | $149 |
| Collegium Pharmaceutical, Inc. | 7 | $137 |
| Idorsia Pharmaceuticals US Inc | 7 | $124 |
| Teva Pharmaceuticals USA, Inc. | 5 | $105 |
| Sunovion Pharmaceuticals Inc. | 5 | $75 |
| Merck | 3 | $45 |
| Biogen | 1 | $27 |
| Harmony Biosciences LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Brainsway Deep TMS$2,299
- Auvelity$123
How this compares
$11,389 in reported general payments places this provider in the 95th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 97 | $147,049 |
| VraylarCariprazine Hcl | 51 | $76,576 |
| Abilify AsimtufiiAripiprazole | 13 | $73,692 |
| CaplytaLumateperone Tosylate | 26 | $50,056 |
| RexultiBrexpiprazole | 36 | $49,169 |
| TrintellixVortioxetine Hydrobromide | 64 | $31,813 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $23,484 |
| Aripiprazole | 171 | $18,742 |
| Bupropion XlBupropion Hcl | 102 | $6,387 |
| BelsomraSuvorexant | 13 | $5,774 |
| Divalproex Sodium ErDivalproex Sodium | 51 | $4,717 |
| Buspirone Hcl | 251 | $3,699 |
| Clozapine | 52 | $3,429 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 23 | $3,091 |
| Lurasidone Hcl | 16 | $2,848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $468 | $147,04997 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti | $1,302 | $122,86149 claims |
| AbbVieVraylar | $2,427 | $76,57651 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $384 | $50,05626 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $395 | $31,81364 claims |
| Axsome Therapeutics, Inc.Auvelity | $532 | $23,48421 claims |
| MerckBelsomra | $45 | $5,77413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Grand Island
- Ashley KennedyGrand Island$6K
- Chelsea JohnsonGrand Island$5K
- Linda BerryGrand Island$5K
- Jennifer MurrayGrand Island$4K
- Kylene SchroerGrand Island$3K
- Dacia OakesonHastings$32K
- Margaret Emersonla Vista$30K
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.